Second case of rare mpox strain discovered in traveller
A case of the Clade 1 strain of mpox has been confirmed in a patient in Queensland's Metro South Hospital and Health Service region, the state's health body said.
The patient is believed to have acquired mpox overseas before arriving in Australia, state Health Minister Tim Nicholls said.
"Contact tracing has been occurring, and the community can be assured that exposure to members of the community has been very limited, and the public should not be concerned," he said on Saturday.
The detection is the second incidence of the mpox strain reported in Australia after a returned traveller tested positive for the virus in NSW in May.
Mpox is a viral infection that typically displays mild symptoms of fever, headache, muscle aches, swollen lymph nodes or fatigue, followed by a skin rash or lesions.
The disease does not easily spread between people and mostly occurs through very close or intimate contact with someone infected.
Groups at higher risk of infection include sexually active gay, bisexual or other men who have sex with men and their partners.
Health authorities say vaccinations for pre- and post-exposure to the disease are effective and are available for free through sexual health clinics and general practitioners.
#mpox remains a public health emergency of international concernThe announcement follows the fourth meeting of the IHR Emergency Committee regarding the upsurge of mpox. The Committee advised the Director-General @DrTedros to extend the public health emergency of international… pic.twitter.com/fPP3duWuuh
— World Health Organization (WHO) (@WHO) June 9, 2025
Two doses of vaccine are needed for optimal protection, with vaccination reducing the risk of infection and severe disease.
The World Health Organization declared the mpox outbreak a public health emergency of international concern in August 2024.
The disease was first detected in Australia in 2022, with the number of cases spiking to more than 1400 in 2024, according to Australia's National Notifiable Disease Surveillance System.
There have been about 150 confirmed cases of mpox in 2025.
Men make up the majority of reported notifications, accounting for more than 1700 of all confirmed cases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
8 hours ago
- Medscape
EMA Launches Review of Tecovirimat Effectiveness for Mpox
The European Medicines Agency (EMA) has initiated a review of Tecovirimat SIGA, also called TPOXX, a medicine used to treat mpox. This follows emerging clinical trial data suggesting a lack of effectiveness. The mpox virus is an orthopoxvirus, a class that includes the smallpox virus. Tecovirimat SIGA was originally approved in the US to treat smallpox. The EMA and the Medicines and Healthcare products Regulatory Agency in the UK authorized its use in January 2022, at the start of an mpox outbreak in Europe, for the treatment of smallpox, mpox, cowpox, and vaccinia complications following smallpox vaccination, in adults and children weighing at least 13 kg. The drug is an oral medicine that interferes with a protein called VP37 found on the surface of orthopoxviruses, preventing them from reproducing normally and thus slowing the spread of infection. No other treatments are authorized for mpox or cowpox infections, which may in rare cases be fatal. European Cases Linked With Risky Sexual Behaviors Mpox is a zoonotic infection occurring mainly in West and Central Africa, with most cases in Europe before 2022 either imported from countries where mpox is endemic or from contacts with documented epidemiological links to imported cases. The outbreak in the EU and UK has been transmitted between humans mainly through sexual contact. It primarily affects gay, bisexual, or other men who have sex with men and who have multiple sexual partners, participate in group sex, or attend sex-on-premises venues. Transmission occurs primarily within interconnected sexual networks. Symptoms of mpox typically appear 1-3 weeks after infection and include fever, headache, chills, physical weakness, lymph node swelling, back pain, and muscle aches, along with a distinct, fast-spreading papular rash on the skin and mucosal sores in the mouth, nose, throat, or digestive tract that then turn into fluid-filled vesicles. Mild-to-moderate symptoms usually last 2-4 weeks and are followed by full recovery, though some people develop permanent scars. During outbreaks, the case fatality of mpox ranges from 0% to 11%. People who are immunocompromised, including those with HIV infection or AIDS, are at a higher risk for severe disease. Exceptional Circumstances Approval During Outbreak Approval for Tecovirimat SIGA was granted under 'exceptional circumstances' provisions, based only on pharmacodynamic and pharmacokinetic studies, because the disease is rare and sporadic, so human studies were not available. A condition of such authorization is that the company marketing Tecovirimat SIGA is required to provide an annual update on benefits and risks. The EMA's review is a postauthorization procedure that involves a scientific assessment by the agency on behalf of the EU aimed at resolving issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In the case of Tecovirimat SIGA (tecovirimat), the review was initiated at the request of the European Commission. The review follows publication of preliminary results from two clinical trials. In the randomized, placebo-controlled PALM007 trial involving 597 children and adults with laboratory-confirmed clade I mpox in the Democratic Republic of the Congo (DRC), results reported in April in The New England Journal of Medicine showed that the drug did not reduce the duration of mpox lesions (median time to resolution, 7 vs 8 days). The overall mortality among enrollees, regardless of whether or not they received the drug, was 1.6% — much lower than that generally reported in the DRC, but this was attributed to hospitalization and high-quality supportive care within the trial. The other trial, STOMP, involved people from multiple countries with mild-to-moderate laboratory-confirmed or presumptive clade II mpox. Again, the active drug did not demonstrate efficacy in time to skin and mucosal lesion resolution compared with placebo. The EMA said that similar results had recently been obtained from another study, UNITY, which also did not indicate faster skin lesion resolution on tecovirimat compared with placebo. Further analyses from ongoing or recently completed studies are still awaited and will also inform the EMA's final assessment.
CNN
a day ago
- CNN
CNN reports from Gaza aid crossing
Concerns grow over Australia's toxic algae bloom A harmful algae bloom off the coast of South Australia, caused by high sea temperatures and runoff from flooding, is poisoning marine life and depleting oxygen in the water. The Australian government has stated that there is little that can be done to reverse the rapid rate of the climate crisis.
Yahoo
2 days ago
- Yahoo
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$439m
MELBOURNE, Australia, July 24, 2025 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia's leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million. Joining existing investors Hesta, Host Plus, CSL and QIC are the WA Government and Australia's sovereign investor in manufacturing capability, the National Reconstruction Fund Corporation (NRFC). This final close of Brandon BioCatalyst Fund Six (BB6) will see Brandon Capital continue to invest in emerging biomedical technologies with strong commercial potential, translating these exciting discoveries into high-growth firms that positively impact human health. To date, Brandon Capital has raised over A$1 billion across previous funds with notable Fund Six investments to date including AdvanCell (radiopharma), PolyActiva (glaucoma implant), Myricx Bio (ADC) and CatalYm (oncology). Dr Chris Nave, Co-Founder and Managing Partner at Brandon Capital, 'We're excited to welcome the National Reconstruction Fund Corporation to our sixth fund, joining HESTA, Hostplus, CSL, QIC and the WA Government. Closing at $439 million, BB6 is our largest fund to date, and we remain committed to advancing breakthrough biomedical innovations through our unwavering scientific rigour and disciplined capital allocation, in pursuit of exceeding our investors' expectations.' The firm has a track record of advancing its portfolio companies to commercialisation. Recent Brandon Capital portfolio company announcements include FDA approvals for a hypertension therapy from George Medicines and a left ventricular cardiac resynchronisation device developed by EBR Systems, with Q-Sera's blood collection tubes that produce high-quality serum faster and more reliably, recently approved in Japan. Brandon Capital has an active portfolio of over 30 companies with 17 in clinical trials, four advancing or in-market, a promising preclinical pipeline and several actively contributing to Australia's high-skilled manufacturing sector growth. Collectively supporting over 270 high-skilled Australian jobs are: surgical imaging innovator, OncoRes Medical, which has developed the first 'real-time' in cavity probe to improve cancer surgery outcomes; late-stage biotech PolyActiva, which is developing a long-term treatment for glaucoma, the second leading cause of blindness; needle-free patch for vaccine delivery Vaxxas, and radiopharmaceutical company AdvanCell, which is developing novel therapies for the treatment of a range of cancers. NRFC CEO David Gall said, "Medical science has long development timelines, and it is important for the NRFC to make early and considered investments in the sector to attract the talent and capital that we will need to build our local commercialisation capabilities. If we want medical science jobs and industries to exist in Australia in ten years, we need to invest in them today." Brandon Capital, headquartered in Australia with offices in the UK and US, has established a transcontinental presence that strengthens collaboration across regions. Australian portfolio companies gain access to UK/EU/US capital, expertise, and pharma networks, while international companies benefit from Australia's world-class clinical trial and research capabilities. About Brandon Capital – Brandon Capital is Australasia's leading life sciences venture capital firm, with offices in Australia, New Zealand, the US and the UK. Its unique model includes proprietary deal flow through Brandon BioCatalyst, a collaboration of over 50 of ANZ's leading medical research institutions, and its immersive corporate services structure enables portfolio companies to focus on research commercialisation. With more than 30 active companies in its portfolio, Brandon Capital has been sourcing and supporting the transition of world-leading science into world-leading businesses for nearly two decades. For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585 Chris Gardner, E: Chris@ M: +44 (0)7956 031077 About the National Reconstruction Fund Corporation (NRFC) The NRFC invests to diversify and transform Australia's industry and economy. It has $15 billion to invest using direct loans, equity investments and loan guarantees. The NRFC investment mandate covers seven priority areas including value-add in resources; transport; medical science; defence capability; renewables and low emission technologies; value-add in agriculture, forestry and fisheries; and enabling capabilities. The NRFC's role is to invest in Australian businesses and projects that design, refine and make in order to transform capability, grow jobs and a skilled workforce, and diversify our economy. NRFC is a corporate Commonwealth entity, established by the National Reconstruction Fund Corporation Act 2023 (NRFC Act) in September 2023. For more information, visit
